Corporate news

Grifols culminates a year of growth and approves the distribution of a record EUR 265 million in dividends Annual General Shareholders' Meeting helds with approximately 80% of share capital represented
+ info

Grifols publishes its 2017 Corporate Responsibility Report as part of its commitment to transparency In alignment with Global Reporting Initiative (GRI) information requirements and recommendations, the report was verified by an external independent firm and approved by Grifols' Board of Directors on April 27, 2018.
+ info

Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents Grifols conventional antisera reagents recently received licensing approval by the U.S. Food & Drug Administration for manual testing in immunohematology laboratories
+ info



We are a solid company with an international dimension.

Corporate Commitment

We contribute to improving people's health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.

When a Dream Comes True. An Illustrated History of 75 Years of Grifols

Read When a Dream Comes True: An illustrated history of 75 years of Grifols to discover the company's roots, and learn more about our history and the development of the company.  + info


get to know us better